Retatrutide vs Tirzepatide: What Can We Compare Yet?

Retatrutide and tirzepatide come from the same company (Eli Lilly) and the same family of incretin-based medicines, so it's natural to want to line them up side by side. But as of October 2026 they're in very different places. Tirzepatide is an approved prescription medicine in the US, sold as Mounjaro and Zepbound, each with its own label. Retatrutide is still investigational and is not FDA-approved.

How are they designed differently?

Tirzepatide is a "dual agonist": one molecule that activates both GIP and GLP-1 receptors. Retatrutide is a "triple agonist" that also activates the glucagon receptor (we unpack that in what a triple agonist is). The extra target is why researchers are so interested, but a mechanism on its own doesn't prove a medicine works better, is safer, or suits any particular person.

What did each drug's main trial find?

Each drug has a large placebo-controlled Phase 3 obesity trial in adults without diabetes:

• Tirzepatide (SURMOUNT-1): 2,539 adults, 72 weeks. Average weight change was −15.0%, −19.5% and −20.9% on 5, 10 and 15 mg, versus −3.1% on placebo.
• Retatrutide (TRIUMPH-1): 2,339 adults, 80 weeks, published in NEJM in September 2026. Average weight change in the main intention-to-treat analysis was −17.6%, −23.7% and −25.0% on 4, 9 and 12 mg, versus −3.9% on placebo. Lilly's press release highlighted a higher figure (up to −28.3%) from an analysis that assumes everyone stayed on treatment.

It's tempting to subtract one from the other, but these were separate trials, run years apart, with different lengths, dose steps and analysis methods. Putting the numbers side by side gives a rough sense of scale, not a winner. Tolerability matters too: Lilly reported that 11.3% of people on retatrutide 12 mg stopped treatment because of side effects, versus 4.9% on placebo, and gastrointestinal effects were the most common. For the full rundown of the retatrutide results, see our retatrutide 2026 trial explainer.

Is there a head-to-head trial?

Yes, and it's the one to watch. TRIUMPH-5 is a randomized, double-blind Phase 3 trial comparing retatrutide directly with tirzepatide in about 800 adults with obesity. Its main outcome is percent change in body weight at week 80. ClinicalTrials.gov lists its primary completion as estimated for November 2026, so as of October 2026 no head-to-head results have been reported. Until they are, any "retatrutide beats tirzepatide" claim is an indirect comparison.

Why approval status matters

An approved medicine has an official label covering who it's for, how it's dosed, its warnings and how it's manufactured. In the US, Mounjaro is approved for type 2 diabetes (and, since August 2026, to reduce major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk), while Zepbound is approved for chronic weight management and moderate-to-severe obstructive sleep apnea with obesity.

Retatrutide has none of that yet. Lilly has said it plans to file with the FDA in the first quarter of 2027, and in August 2026 it opened a limited expanded-access (compassionate-use) program, which is case-by-case access to an investigational drug, not a retail launch. Products sold online as "retatrutide" or "research peptides" aren't the medicine studied in trials, and their identity, purity and dose can't be verified. Our guide to compounded and unapproved GLP-1 red flags covers what to look out for.

The takeaway

Retatrutide's results are genuinely notable, but the fair answer today is that we can't rank it against tirzepatide yet. The head-to-head trial and a regulatory decision will tell us far more than any headline. If you're taking tirzepatide now, news about a future medicine isn't a reason to change anything on your own; bring your questions to your prescriber.